Yann Duchesne

About Yann Duchesne

Yann Duchesne is the Chairman of the Board of Theraclion, a French listed medtech company focused on non-invasive ultrasound-based treatments. He joined Theraclion’s governance in January 2022, when the company announced his appointment as Chairman following a change in leadership, and then served as Executive Chairman as Theraclion entered a new strategic phase. Theraclion’s current corporate materials still identify him as Chairman of the Board. His background reflects the profile of a seasoned French executive with deep experience in consulting, private equity and corporate leadership. Theraclion describes him as a former Managing Partner at McKinsey in France, later a Senior Partner at a leading London-based private equity firm, before becoming CEO of a major industrial and commercial conglomerate. The company also notes that over the past two decades he has served on many boards of listed and private-equity-backed companies, often as chairman. In healthcare, Yann Duchesne brings substantial exposure to pharmaceuticals and medtech. Theraclion states that he advised major pharmaceutical groups during his McKinsey years, chairs a pharmaceutical group called Medis, and is a founding shareholder of a California-based biotech, Phylex. That combination of strategic, financial and sector-specific experience is particularly relevant for a company like Theraclion, where success depends on clinical validation, regulatory execution, industrial discipline and commercial scale-up. At Theraclion, he has promoted a strategy built around three therapeutic areas and three geographies, with a strong emphasis on varicose veins, thyroid applications and breast cancer. Company documents explain that he steered the organization toward improving technology performance and clinical outcomes, accessing the U.S. market, standardizing treatment protocols in Europe, and securing financing and strategic partnerships. The ambition was to position Theraclion among the world leaders in therapeutic devices combining robotics and artificial intelligence. Overall, Yann Duchesne’s role at Theraclion is best understood as a governance-and-transformation mandate. He represents a corporate leader with a strong track record in strategy, financing and board oversight, particularly suited to the demands of a publicly listed medtech company navigating innovation, international expansion and capital-intensive development.